title: Pros and cons of drugs that prolong ventricular refractoriness.
authors: Med. Univ. Klinik, Heidelberg, Germany.
authors: J
authors: J
authors: Brachmann
authors: T
authors: T
authors: Beyer
authors: W
authors: W
authors: Schöls
authors: C
authors: C
authors: Schmitt
authors: M
authors: M
authors: Montero
authors: W
authors: W
authors: Knollmann
authors: T
authors: T
authors: Hilbel
authors: W
authors: W
authors: Kübler
mesh_terms: D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004285:Dogs; D006352:Heart Ventricles / Q000187:drug effects; D006801:Humans; D012032:Refractory Period, Electrophysiological / Q000187:drug effects*; D013610:Tachycardia / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D000889:Anti-Arrhythmia Agents